These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8831756)

  • 1. Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone.
    Hulin B; Newton LS; Lewis DM; Genereux PE; Gibbs EM; Clark DA
    J Med Chem; 1996 Sep; 39(20):3897-907. PubMed ID: 8831756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents.
    Clark DA; Goldstein SW; Volkmann RA; Eggler JF; Holland GF; Hulin B; Stevenson RW; Kreutter DK; Gibbs EM; Krupp MN
    J Med Chem; 1991 Jan; 34(1):319-25. PubMed ID: 1992133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
    Pingali H; Jain M; Shah S; Makadia P; Zaware P; Goel A; Patel M; Giri S; Patel H; Patel P
    Bioorg Med Chem; 2008 Aug; 16(15):7117-27. PubMed ID: 18625559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones.
    Sohda T; Momose Y; Meguro K; Kawamatsu Y; Sugiyama Y; Ikeda H
    Arzneimittelforschung; 1990 Jan; 40(1):37-42. PubMed ID: 2339998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides.
    Ellinboe JW; Alessi TR; Dolak TM; Nguyen TT; Tomer JD; Guzzo F; Bagli JF; McCaleb ML
    J Med Chem; 1992 Apr; 35(7):1176-83. PubMed ID: 1560432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
    Aicher TD; Balkan B; Bell PA; Brand LJ; Cheon SH; Deems RO; Fell JB; Fillers WS; Fraser JD; Gao J; Knorr DC; Kahle GG; Leone CL; Nadelson J; Simpson R; Smith HC
    J Med Chem; 1998 Nov; 41(23):4556-66. PubMed ID: 9804695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives.
    Imoto H; Imamiya E; Momose Y; Sugiyama Y; Kimura H; Sohda T
    Chem Pharm Bull (Tokyo); 2002 Oct; 50(10):1349-57. PubMed ID: 12372861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perfluorocarbon-based antidiabetic agents.
    Kees KL; Smith TM; McCaleb ML; Prozialeck DH; Cheeseman RS; Christos TE; Patt WC; Steiner KE
    J Med Chem; 1992 Mar; 35(5):944-53. PubMed ID: 1548684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
    Oguchi M; Wada K; Honma H; Tanaka A; Kaneko T; Sakakibara S; Ohsumi J; Serizawa N; Fujiwara T; Horikoshi H; Fujita T
    J Med Chem; 2000 Aug; 43(16):3052-66. PubMed ID: 10956213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models.
    Chang AY; Wyse BM
    Prog Clin Biol Res; 1988; 265():177-92. PubMed ID: 3043443
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a new class of benzoylpyrrole-based PPARα/γ activators.
    Ushiroda K; Maruta K; Kitoh M; Iwai K; Nagamine J; Tsuchida A; Taiji M; Nagata R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):220-4. PubMed ID: 21130649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidinediones.
    Zask A; Jirkovsky I; Nowicki JW; McCaleb ML
    J Med Chem; 1990 May; 33(5):1418-23. PubMed ID: 2329563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhodium carbene routes to oxazoles and thiazoles. Catalyst effects in the synthesis of oxazole and thiazole carboxylates, phosphonates, and sulfones.
    Shi B; Blake AJ; Lewis W; Campbell IB; Judkins BD; Moody CJ
    J Org Chem; 2010 Jan; 75(1):152-61. PubMed ID: 19954177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
    Cantello BC; Cawthorne MA; Cottam GP; Duff PT; Haigh D; Hindley RM; Lister CA; Smith SA; Thurlby PL
    J Med Chem; 1994 Nov; 37(23):3977-85. PubMed ID: 7966158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of potent retinoid X receptor alpha agonists.
    Haffner CD; Lenhard JM; Miller AB; McDougald DL; Dwornik K; Ittoop OR; Gampe RT; Xu HE; Blanchard S; Montana VG; Consler TG; Bledsoe RK; Ayscue A; Croom D
    J Med Chem; 2004 Apr; 47(8):2010-29. PubMed ID: 15056000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
    J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
    Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
    Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
    Collins JL; Blanchard SG; Boswell GE; Charifson PS; Cobb JE; Henke BR; Hull-Ryde EA; Kazmierski WM; Lake DH; Leesnitzer LM; Lehmann J; Lenhard JM; Orband-Miller LA; Gray-Nunez Y; Parks DJ; Plunkett KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5037-54. PubMed ID: 9836621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.